Keyword Analysis & Research: checkmate 648
Keyword Research: People who searched checkmate 648 also searched
Search Results related to checkmate 648 on Search Engine
-
Nivolumab Combination Therapy in Advanced Esophageal …
https://www.nejm.org/doi/full/10.1056/NEJMoa2111380
WebFeb 2, 2022 · CheckMate 648 is a global phase 3 trial that evaluated the efficacy and safety of both an immune checkpoint inhibitor in combination with chemotherapy and a dual immune checkpoint inhibitor...
DA: 42 PA: 91 MOZ Rank: 92
-
Nivolumab Combination Therapy in Advanced Esophageal …
https://pubmed.ncbi.nlm.nih.gov/35108470/
WebFeb 3, 2022 · (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 648 ClinicalTrials.gov number, NCT03143153 .). Copyright © 2022 Massachusetts Medical Society. Publication types. Clinical Trial, Phase III. Randomized Controlled Trial. Research Support, Non-U.S. Gov't. MeSH terms. Adult. Aged, 80 and over.
DA: 97 PA: 9 MOZ Rank: 67
-
First-line nivolumab plus ipilimumab or chemotherapy versus
https://pubmed.ncbi.nlm.nih.gov/36401133/
WebCheckMate 648, a global, phase 3 trial, showed that first-line nivolumab (anti-PD-1 antibody) plus ipilimumab (NIVO + IPI) or nivolumab plus chemotherapy (NIVO + Chemo) significantly increased survival in advanced esophageal squamous cell carcinoma (ESCC) without new safety signals versus chemotherapy alone (Chemo).
DA: 35 PA: 66 MOZ Rank: 43
-
CheckMate 648: A randomized phase 3 study of nivolumab plus …
https://ascopubs.org/doi/10.1200/JCO.2018.36.4_suppl.TPS193
WebFeb 26, 2018 · CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma. | Journal of Clinical Oncology.
DA: 74 PA: 11 MOZ Rank: 10
-
Nivolumab in Esophageal Squamous-Cell Carcinoma | NEJM
https://www.nejm.org/doi/full/10.1056/NEJMc2202880
WebMay 18, 2022 · Abstract. To the Editor: The results of the CheckMate 648 trial reported by Doki et al. (Feb. 3 issue) 1 showed longer overall survival with nivolumab plus chemotherapy or with nivolumab plus...
DA: 40 PA: 20 MOZ Rank: 72
-
Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab …
https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.252
WebJan 22, 2024 · Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.. JCO 42, 252-252 (2024).
DA: 57 PA: 32 MOZ Rank: 27
-
CheckMate 648: First-Line Nivolumab Regimens Improve Survival …
https://ascopost.com/issues/june-25-2021/checkmate-648-first-line-nivolumab-regimens-improve-survival-in-esophageal-squamous-cell-carcinoma/
WebJun 25, 2021 · About CheckMate 648. CheckMate 648 attempted to improve upon the poor prognosis of current first-line treatments, which yield median overall survival times of about 10 months. The study randomly assigned 970 patients irrespective of PD-L1 expression to one of three treatment arms: nivolumab at 240 mg every 2 weeks plus chemotherapy …
DA: 35 PA: 2 MOZ Rank: 26
-
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab …
https://ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.290
WebJan 24, 2023 · Background: NIVO + chemo and NIVO + IPI demonstrated superior overall survival (OS) vs chemo in CheckMate 648 (NCT03143153), leading to approvals in the US, EU, Japan, and other countries. We report longer follow-up results. Methods: Adults with previously untreated, unresectable advanced, recurrent, or metastatic ESCC were …
DA: 69 PA: 56 MOZ Rank: 62
-
FDA approves Opdivo in combination with chemotherapy and …
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal
WebMay 31, 2022 · CHECKMATE-648 demonstrated statistically significant improvements in OS in all randomized patients and in the subpopulation with tumor cell (TC) PD-L1 ≥1% for both nivolumab-containing regimens...
DA: 20 PA: 36 MOZ Rank: 83
-
OPDIVO® (nivolumab) + Chemo Checkmate 648 Efficacy Data …
https://www.opdivohcp.com/efficacy/gastro/opdivo-chemo/648
WebView efficacy information from the Checkmate 648 clinical trial for OPDIVO® (nivolumab) + chemotherapy (fluoropyrimidine- and platinum-containing) in metastatic ESCC. Please see Indications and Important Safety Information.
DA: 35 PA: 93 MOZ Rank: 2
